His scientific interests lie mostly in Psoriasis, Immunology, Internal medicine, Severity of illness and Dermatology. His Psoriasis study combines topics in areas such as Genetics, Genome-wide association study and Surgery. As a member of one scientific family, Ulrich Mrowietz mostly works in the field of Immunology, focusing on Receptor and, on occasion, Transcription factor, Downregulation and upregulation and Aryl hydrocarbon receptor.
His Internal medicine research focuses on Placebo and how it connects with Apremilast. His Severity of illness research integrates issues from Quality of life and Intensive care medicine. His studies deal with areas such as Etanercept and MEDLINE as well as Dermatology.
Ulrich Mrowietz mostly deals with Psoriasis, Dermatology, Internal medicine, Immunology and Psoriasis Area and Severity Index. In his research on the topic of Psoriasis, Comorbidity is strongly related with Disease. His study in Dermatology is interdisciplinary in nature, drawing from both Infliximab and MEDLINE.
Ulrich Mrowietz frequently studies issues relating to Placebo and Internal medicine. His Chemotaxis research extends to the thematically linked field of Immunology. His Dermatology Life Quality Index research is under the purview of Quality of life.
His primary scientific interests are in Psoriasis, Internal medicine, Dermatology, Psoriasis Area and Severity Index and Secukinumab. His work carried out in the field of Psoriasis brings together such families of science as Quality of life, Disease and Family medicine. His work on Inflammatory bowel disease is typically connected to Systemic therapy as part of general Disease study, connecting several disciplines of science.
He usually deals with Internal medicine and limits it to topics linked to Placebo and Clinical endpoint and Nail. His research integrates issues of Plaque psoriasis and Clinical trial in his study of Psoriasis Area and Severity Index. He works mostly in the field of Secukinumab, limiting it down to topics relating to Ustekinumab and, in certain cases, Acitretin, Apremilast, Etanercept and Intensive care medicine.
The scientist’s investigation covers issues in Psoriasis, Internal medicine, Dermatology, Psoriasis Area and Severity Index and Secukinumab. The study incorporates disciplines such as Body surface area, Severity of illness and Disease in addition to Psoriasis. His Disease research is multidisciplinary, relying on both Interleukin and Metabolic syndrome.
His work on Papulopustular rosacea as part of general Dermatology research is frequently linked to Systemic therapy, thereby connecting diverse disciplines of science. His study focuses on the intersection of Psoriasis Area and Severity Index and fields such as Plaque psoriasis with connections in the field of Methotrexate and Fumaric Acid Esters. His Secukinumab research includes themes of Infliximab, Ustekinumab, Apremilast, Placebo and Acitretin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
Lam C. Tsoi;Sarah L. Spain;Sarah L. Spain;Jo Knight;Eva Ellinghaus;Eva Ellinghaus.
Nature Genetics (2012)
Definition of treatment goals for moderate to severe psoriasis: a European consensus
U. Mrowietz;K. Kragballe;K. Reich;P. Spuls.
Archives of Dermatological Research (2011)
European S3-guidelines on the systemic treatment of psoriasis vulgaris
D Pathirana;AD Ormerod;P Saiag;Catherine Smith.
Journal of The European Academy of Dermatology and Venereology (2009)
Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci
David Ellinghaus;Luke Jostins;Sarah L. Spain;Adrian Cortes.
Nature Genetics (2016)
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease
Kamran Ghoreschi;Peter Thomas;Susanne Breit;Martin Dugas.
Nature Medicine (2003)
Quality of life of patients with keloid and hypertrophic scarring.
Oliver Bock;Gerhard Schmid-Ott;Peter Malewski;Ulrich Mrowietz.
Archives of Dermatological Research (2006)
European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC
A Nast;P Gisondi;A D Ormerod;P Saiag.
Journal of The European Academy of Dermatology and Venereology (2015)
Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Parallel Randomized Trial
Alexa B. Kimball;Francisco Kerdel;David Adams;Ulrich Mrowietz.
Annals of Internal Medicine (2012)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
C Paul;J Cather;M Gooderham;Y Poulin.
British Journal of Dermatology (2015)
Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation
Henrik Wilms;Jobst Sievers;Uta Rickert;Martin Rostami-Yazdi.
Journal of Neuroinflammation (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: